



Supplemental Figure 3


A




B



C



D



Supplemental Figure 3 | Verification of depletions

A, Representative plots and bar chart for CD45⁺CD11b⁺F4/80⁺ TAMs in MOC2 tumors harvested 16 days post-RT with RT or RT + anti-CSF1R treatment. **B**, Representative plots and bar chart for CD45⁺CD11b⁺Ly-6C^{hi}Ly-6G⁻ M-MDSCs or CD45⁺CD11b⁺Ly-6C^{mid}Ly-6G⁺ PMN-MDSCs in blood collected from live C57Bl/6 mice 1 day pre-implantation with anti-Gr-1 treatment versus untreated controls. **C**, Representative plots and bar chart for CD45⁺CD3⁺CD4⁺ T cells or CD45⁺CD3⁺CD8⁺ T cells in blood collected from live mice bearing MOC2 tumors 14 days post-RT with RT or RT + anti-CD25 + anti-CD137 + anti-CD4 + anti-CD8 treatment. **D**, Representative plots and bar chart for CD45⁺CD4⁺Foxp3⁺ Tregs in blood collected from live mice bearing MOC2 tumors 19 days post-implantation with DT treatment vs untreated controls.